Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on January 21, 2026, reporting events that occurred on January 16, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Florham Park, New Jersey. Its Class A Common Stock (CELU) and Warrants (CELUW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and compensation matter rather than financial performance.
Material Changes
The primary material change reported is the approval by the Compensation Committee of the Board of Directors regarding the employment terms of John Haines, Senior Executive Vice President, Global Manager, and Chief Administrative Officer. The First Amendment to his Amended and Restated Employment Agreement includes the following changes:
- Severance period increased from 12 months to 24 months.
- COBRA payment coverage increased to 18 months.
- Equity options owned by Mr. Haines will vest immediately upon termination, rather than over a 24-month period following termination.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, or specific risk factors beyond the implications of the executive compensation amendment. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Verify the total potential cost impact of the increased severance and COBRA benefits for Mr. Haines on the Company's future cash flow.
- Confirm the number of equity options held by Mr. Haines that are subject to immediate vesting upon termination.
- Review the Company's overall executive compensation policy to determine if similar amendments are being applied to other senior officers.